The Boston Globe

Business

Boston.com

INNOVATION ECONOMY

Testing vaccine to block nicotine

By Scott Kirsner

 |  Globe Correspondent  

  November 27, 2011

Selecta Biosciences, a Watertown company announced last week that it had begun the first clinical trial of SEL-068, a nicotine vaccine. In the same way a flu vaccine revs up your body’s immune system to round up flu viruses, Selecta’s vaccine would train the immune system to capture nicotine molecules in the bloodstream, barring them from entering your brain. Smoking a cigarette would have none of the calming, appetite-reducing, or focus-sharpening effects that smokers seek.

Stay with the story. Get full access to BostonGlobe.com for just 99¢

Unlimited access to BostonGlobe.com for only 99¢ for the first 4 weeks. You can cancel at any time.

  • The FULL story all day: Enjoy all of the high-quality, in-depth journalism in the print edition of the Boston Globe — plus breaking news that's updated 24/7.
  • A truly reader-friendly format: It's online news that looks and reads just like the newspaper — uncluttered, uninterrupted.
  • Breakthrough technology: The responsive design automatically adapts content so it always reads perfectly on the digital device of your choice.
Get started today

Free access for home delivery subscribers.

Just need to link your home delivery account; one easy step.

Link my home delivery account

BostonGlobe.comSubscriber Log In

Contact us for help